Boehringer Ingelheim nabs US approval for COPD combo
- Boehringer Ingelheim has won FDA approval of the Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray, a once-daily treatment for chronic obstructive pulmonary disorder (COPD).
- This is the only COPD treatment with tiotropium, the active ingredient in Spiriva.
- Stiolto Respimat is positioned to be used starting at the time of diagnosis with COPD as a maintenance treatment.
Experts anticipate that by 2030, COPD will be the third leading cause of death worldwide. Currently, COPD, which includes chronic bronchitis and emphysema, affects 210 million people worldwide.
The use of tiotropium, a long-lasting anticholinergic with reams of data supporting its effectiveness and safety in use for pulmonary disorders, makes Stiolto Respimat a novel treatment option for sufferers of COPD. More than 15,000 people with COPD have been tested in clinical trials with Stiolto Respimat—and the results show that use of this therapy enhances lung function across a range of severities.